Bahmer 1992.
Study characteristics | ||
Methods | Design: randomised, placebo‐controlled, parallel Duration: 3 months Interval of assessment: baseline, 6 weeks, 3 months This was a randomised controlled trial |
|
Participants | Number randomised: 12 (7 in the active group and 5 in the placebo group) Sex (M/F): 6/6 total (3/4 in the active group and 3/2 in the placebo group) Age of participants: active group = 31 (mean), placebo group = 27 (mean) Unit of allocation: whole person Country and setting: Saarlandes, Germany; single university dermatology clinic Inclusion criteria of the study (specified)
Exclusion criteria of the study
|
|
Interventions |
|
|
Outcomes |
|
|
Notes | Previous treatment was not stopped ("no limitations regarding other treatment were required") Assessment of compliance was not undertaken |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | The trial mentioned randomisation, but did not give a specific method |
Allocation concealment (selection bias) | Unclear risk | The trial did not give a method for allocation concealment |
Incomplete outcome data (attrition bias) All outcomes | Low risk | There were no dropouts or losses to follow up (7/7 glandol and 5/5 placebo completed) |
Selective reporting (reporting bias) | Low risk | The trial reported all outcomes |
Other bias | Low risk | All randomised participants were included in the analysis in the groups to which they were randomised. We contacted the author |
Blinding of participants and personnel (performance bias) All outcomes | Low risk | This was adequate as both the participant and assessor were blinded |